Myopia Control Efficacy of Spectacle Lenses With Aspherical Lenslets: Results of a 3-Year Follow-Up Study

屈光度 医学 眼科 奇观 随机对照试验 外科 视力 市场经济 经济
作者
Xue Li,Yingying Huang,Ziang Yin,Chenyao Liu,Siqi Zhang,Adeline Yang,Björn Drobe,Hao Chen,Jinhua Bao
出处
期刊:American Journal of Ophthalmology [Elsevier]
卷期号:253: 160-168 被引量:36
标识
DOI:10.1016/j.ajo.2023.03.030
摘要

To investigate myopia control efficacy in children who continued wearing spectacle lenses with highly aspherical lenslets (HAL) or switched from spectacle lenses with slightly aspherical lenslets (SAL) and single-vision spectacle lenses (SVL) to HAL for 1 year after a 2-year myopia control trial.This was a 1-year extension of a randomized clinical trial.Of 54 children who had worn HAL for 2 years, 52 continued wearing HAL (HAL1 group), and of the 53 and 51 children who had originally worn SAL or SVL, 51 and 48 switched to wearing HAL (HAL2 and HAL3 groups) in year 3, respectively. A new SVL (nSVL) group of 56 children was recruited, matched for age, sex, cycloplegic spherical equivalent refraction (SER), and axial length (AL) of the HAL3 group at extension baseline, and used for a comparison of third-year changes. SER and AL were measured every 6 months in year 3.During year 3, the mean (SE) myopia progression in the nSVL group was -0.56 (0.05) diopters (D). Compared with nSVL, the changes in SER were less in HAL1 (-0.38 [0.05] D, P = .02), HAL2 (-0.36 [0.06] D, P = .01), and HAL3 (-0.33 [0.06] D, P = .005). The mean (SE) AL elongation in the nSVL group was 0.28 (0.02) mm. Compared with nSVL, the elongation in AL was less in the HAL1 (0.17 [0.02] mm, P < .001), HAL2 (0.18 [0.02] mm, P < .001), and HAL3 (0.14 [0.02] mm, P < .001) groups. Myopia progression and axial elongation were comparable in all 3 HAL groups (all P > .05) in year 3.Myopia control efficacy has remained in children who wore HAL in the previous 2 years. Children who switched from SAL or SVL to HAL in year 3 had slower myopia progression and axial elongation than that in the control group.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
辛勤的无血完成签到,获得积分10
4秒前
5秒前
rookie完成签到,获得积分10
5秒前
5秒前
ni完成签到,获得积分10
6秒前
step_stone给step_stone的求助进行了留言
7秒前
7秒前
荒野星辰发布了新的文献求助10
8秒前
敏感的芷完成签到,获得积分20
8秒前
10秒前
10秒前
11秒前
luoshi应助沐风采纳,获得20
11秒前
安南完成签到,获得积分10
11秒前
香蕉冬云完成签到 ,获得积分10
12秒前
自信安荷发布了新的文献求助200
12秒前
鱼雷发布了新的文献求助10
13秒前
兔子发布了新的文献求助10
13秒前
13秒前
田様应助coffee采纳,获得10
14秒前
14秒前
专注鼠标完成签到,获得积分10
14秒前
LingYing完成签到 ,获得积分10
15秒前
cheche完成签到,获得积分10
16秒前
liushun完成签到,获得积分10
16秒前
caoyy发布了新的文献求助10
16秒前
zzt发布了新的文献求助10
17秒前
19秒前
19秒前
章家炜发布了新的文献求助10
20秒前
脑洞疼应助xfxx采纳,获得10
20秒前
wanci应助茶博士采纳,获得10
20秒前
所所应助YYT采纳,获得10
21秒前
匿名网友完成签到 ,获得积分10
21秒前
雪白雍完成签到,获得积分10
22秒前
maomao完成签到,获得积分10
22秒前
我是笨蛋完成签到 ,获得积分10
24秒前
酷波er应助caoyy采纳,获得10
25秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527990
求助须知:如何正确求助?哪些是违规求助? 3108173
关于积分的说明 9287913
捐赠科研通 2805882
什么是DOI,文献DOI怎么找? 1540119
邀请新用户注册赠送积分活动 716941
科研通“疑难数据库(出版商)”最低求助积分说明 709824